Posted inBiotechnology
US government pumps money toward in vivo cell therapy programs
After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into…
Posted inBiotechnology
Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk
New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated with Alzheimer’s disease. Amongst…
Posted inMedical Technology
BD, Opentrons Labs enter multi-year collaboration to join cell analysis, automation tech
Under a multi-year deal, medtech company BD and lab automation specialist Opentrons Labworks are joining forces to leverage their respective…
Posted inMedical Technology
Oxford BioDynamics unveils new target use for EpiSwitch blood test
Oxford BioDynamics, a U.K.-based maker of precision diagnostics, touted progress toward a first-of-its-kind blood test for chronic fatigue syndrome (CFS)—also…
Posted inBiotechnology
Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026
Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the…
Posted inBiotechnology
TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine
In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a…
Posted inBiotechnology
Immunology biotech Nilo launches with $101M and mission to harness neural circuits
Nilo Therapeutics has launched with $101 million in series A funds to drive its ambition to harness neural circuits to…
Posted inBiotechnology
Sanofi’s $110M radioligand therapy hits response rate goal in phase 2 tumor trial
Sanofi’s $110 million bet on a radioligand seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints…
Posted inMedical Technology
Alpenglow teams up with Virdx to boost prostate cancer diagnosis with Nvidia, AI power
Alpenglow Biosciences has penned a new, multiyear strategic agreement with Virdx to create the next generation of artificial-intelligence-powered tools aimed…
Posted inBiotechnology
After high-profile FDA exit, Peter Marks lands at Eli Lilly
Peter Marks, M.D., Ph.D., the former head of the FDA’s Center for Biologics Evaluation and Research (CBER), has joined Eli…